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Background. Patients with epithelial ovarian cancer have a high risk of (non-)melanoma skin cancer. The association between
histological variants of primary ovarian cancer and skin cancer is poorly documented. Objectives. To further evaluate the risk of
skin cancer based on the histology of the epithelial ovarian cancer. Methods. A cross-sectional study within a large population-
based dataset. Results. Skin cancer was found in 2.7% (95% CI: 2.3–3.1) of the 5366 individuals forming our dataset. The odds
ratio (OR) for endometrioid cancer in the ovary to skin cancer in the under 50 age group was 8.9 (95% CI: 3.2–25.0). The OR
decreased in older patients to 1.2. Conclusions. Patients with epithelial ovarian malignancies show an increased risk of skin cancer.
A significantly increased risk (4.3%) for endometrioid ovarian cancer was found in the group aged under 50.
1. Introduction
Epidemiological evidence suggests that individuals with skin
cancers have a greater risk of developing other malignancies
[1–6]. This is demonstrated for basal cell cancer, squamous
cell cancer, and (non-)melanoma skin cancer. For post-
menopausal women with nonmelanoma skin cancer, an odds
ratio of 2.01 (95% CI: 1.61–2.50) was calculated for the
association with all forms of ovarian epithelial cancers [6].
According to the sparse literature, which mainly consists
of case series, the presence of primary histological ovarian
carcinoma types and skin cancer is not well documented.
More recently, Van Niekerk et al. [7] estimated excess risks of
melanoma skin cancer (observed/expected ratio = 7.4) and
non-melanoma skin cancer (basal cell cancer included; O/E
= 1.6) for patients with epithelial ovarian cancer. This strong
relationship prompted us to further evaluate the risk of skin
cancer based on the histological type of epithelial ovarian
cancer we have recently studied [8].
2. Materials andMethods
We examined the various histopathological types of epi-
thelial ovarian cancer in relation to primary skin cancers
using the Dutch nationwide pathology database (PALGA—
Pathologisch Anatomisch Landelijk Geautomatiseerd Ar-
chief). Every record in the PALGA database contains a
summary of the full pathology report and diagnostic codes
similar to the Systematized Nomenclature of Medicine
(SNOMED) classification of the College of American Pathol-
ogists. Because of the laborious nature of the review research,
we used two random samples from PALGA.
From the first random sample of the years 1987–1993,
we investigated 4577 patients. For the more recent years
1996–2003, we studied a smaller number of 789 cases to
see whether the overall picture has changed. For these 5366
patients diagnosed with malignant or borderline malignant
epithelial ovarian cancer, we also retrieved all the other
histopathologically confirmed diagnoses of primary invasive
malignancies of the skin diagnosed prior to, concurrent with,
or after the ovarian tumour diagnosis. We reviewed both
the diagnostic codes in the PALGA database and the corre-
sponding pathology conclusions, that is, PALGA code and
PALGA conclusion. This was also done for the skinmalignant
occurring neoplasms. Two experienced pathologists (G. P. V.,
J. Bulten) assessed all reports. Cases were excluded, if we were
not sure that we were dealing with ametastasis of the primary
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Table 1: Patients with epithelial ovarian cancers according to histological type and the occurrence of skin cancer.
Ovarian cancer Basal cell carcinoma Melanoma Other skin cancer Total skin cancer
Histological type of
ovarian cancer
n n n n n % 95% CIa
Adenocarcinoma 1456 25 0 8 33 2.3 1.5–3.1
Clear cell carcinoma 236 6 0 1 7 3.0 0.8–5.2
Endometrioid
carcinoma
460 12 4 4 20 4.3 2.4–6.2
Mucinous carcinomab 733 10 5 3 18 2.5 1.4–3.7
Serous carcinoma 1640 38 4 7 49 3.0 2.2–3.9
Serous b.m. 161 1 0 0 1 0.6 0.0–7.0
Othersb,c 680 12 3 2 17 2.5 1.3–3.7
Total 5366 104 16 25 145 2.7 2.3–3.1
a
95% CI, confidence interval.
bBorderline malignancies included.
cIncluding mixed carcinoma, anaplastic carcinoma, malignant Brenner tumour, carcinosarcoma, adenosquamous carcinoma, squamous cell carcinoma.
Table 2: Odds ratio of endometrioid versus other ovarian carcinoma in relation to skin cancer and age at diagnosis of ovarian cancer.
Skin cancer Skin cancer
<50 yr ≥50 yr
Ovarian cancer total yes no total yes no
Endometrioid carcinoma 122 7 115 338 13 325
All other histological types 1177 8 1169 3729 117 3612
OR = 8.9 = (7× 1169)/(8× 115) OR = 1.2 = (13× 3612)/(117× 325)
95% CI: (3.2–25.0) 95% CI: (0.7–2.2)
X2 = 24.76; P-value = .0001 X2 = .50; P-value = .24
malignant tumour of the ovary or a new secondary type of a
tumour of the ovaries.
The Scientific Committee of PALGA approved the study
protocol.
2.1. Data Analysis. First, we applied descriptive analysis to
the PALGA records of patients having ovarian epithelial can-
cer and/or skin cancer. The association between histological
type and the occurrence of skin cancer was evaluated by
calculating the odds ratios.
95% confidence intervals were calculated to address the
precision of the estimated cancer rate and the relation
between ovarian subtypes and skin cancer. The chi-square
test was used to determine P values.
3. Results
In this study, 5366 cases of primary epithelial malignant
ovarian cancer were selected from the PALGA registry, 4577
in the period 1987–1993 and 789 in the period 1996–2003.
Of these 5366 patients, 145 cases of a second primary skin
malignancy were reported. Analysis of the data from each
period showed that disease occurrence between 1996 to 2003
did not diﬀer from that of the larger database from 1987 to
1993. We therefore merged both datasets.
The 5366 individuals showed an occurrence rate of
skin cancer of 2.7% (95% CI: 2.3–3.1); see Table 1. For
the various subtypes of ovarian carcinoma, the rates for
skin cancer were adenocarcinoma, 2.3% (95% CI: 1.5–3.1);
clear cell carcinoma, 3.0% (95% CI: 0.8–5.2); endometrioid
carcinoma, 4.3% (95% CI: 2.4–6.2); mucinous carcinoma,
2.5% (95% CI: 4–3.7); serous carcinoma, 3.0 (95% CI: 2.2–
3.9); remainder types, 2.5% (95% CI 1.3–3.7). However,
endometrioid ovarian carcinoma showed a significantly
increased risk compared to the other types: P value = .02.
In Table 2, an odds ratio of 8.9 (95% CI: 3.2–25.0) was
calculated for endometrioid carcinoma in the ovary in
relation to skin cancer in patients younger than 50. In
patients older than 50, the odds ratio decreased to 1.2.
4. Discussion
Our population-based study included all incident cases of
basal cell carcinoma (104), melanoma (16), and other skin
cancers (squamous cell carcinoma and Morbus Bowen,
together 25) reported in the PALGA sample of 5366 ovarian
cancer patients between 1987–1996 and 1996–2003. This
study focused on the risk of skin cancer in ovarian cancer
patients according to histological type as recently reported
by Van Niekerk et al. [7], who calculated the observed versus
ISRN Obstetrics and Gynecology 3
expected risk for melanoma skin cancer to be 7.4 and for
basal cell cancer 1.6.
The reasons for these increases are probably manyfold.
In general, an association between skin cancer and a second
primary cancer could reflect shared etiologic factors or
biased ascertainment of new primaries as a result of increased
surveillance [4, 9]. Immune suppression induced by therapy,
exposure to ultraviolet radiation, and the primary disease
could explain some cases. It should also be noted that
individuals who are at high risk of skin cancer may have
other risk-taking behaviours related to their increase in
risk of a second primary cancer such as smoking, dietary
intake, and physical activity levels [10]. The relationship with
endometrioid ovarian carcinoma may however be more due
to common genetic predisposition rather than secondary
contributors such as chemotherapy and smoking.
In the sparse literature on ovarian cancer, and the
occurrence of skin cancer most studies have been conducted
in patients with a primary skin cancer and a new second
primary ovarian cancer [1, 4, 6, 10–13]. Nugent et al. [11]
concluded that females with a history of basal cell carcinoma
were at greater risk of dying from ovarian cancer. Our results
show that patients with epithelial ovarian malignancies
show an increased risk for skin cancer, especially the group
of patients with endometrioid carcinoma. Therefore, we
suggest a careful surveillance of skin lesions in malignant
epithelial ovarian cancer patients, in particular in patients
with endometrioid ovarian carcinoma. Our study should
stimulate new projects on shared carcinogenic pathways.
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